Because overactivation of the immune system and elevated serum levels of inflammatory cytokines, i.e., IL-6 and IL-1, are involved in the pathophysiology of CRS, systemic administration of corticosteroids, blockade of the IL-6 receptor, and generation of engineered CAR T cells that secret IL-1 receptor antagonists have all been proposed as ways to manage the side effects [182]. The gene discussed is IL6; the disease is congenital rubella syndrome.